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Abstract
Background: Coiled-coil domain containing 115 (Ccdc115) or coiled coil protein-1 (ccp1) was previously identified
as a downstream gene of Fibroblast Growth Factor 2 (FGF2) highly expressed in embryonic and adult brain.
However, its function has not been characterised to date. Here we hypothesized that ccp1 may be a downstream
effecter of FGF2, promoting cell proliferation and protecting from apoptosis.
Methods: Forced ccp1 expression in mouse embryonic fibroblast (MEF) and neuroblastoma SK-N-SH cell line, as
well as down-regulation of ccp1 expression by siRNA in NIH3T3, was used to characterize the role of ccp1.
Results: Ccp1 over-expression increased cell proliferation, whereas down-regulation of ccp1 expression reduced it.
Ccp1 was able to increase cell proliferation in the absence of serum. Furthermore, ccp1 reduced apoptosis upon
withdrawal of serum in SK-N-SH. The mitogen-activated protein kinase (MAPK) or ERK Kinase (MEK) inhibitor, U0126,
only partially inhibited the ccp1-dependent BrdU incorporation, indicating that other signaling pathway may be
involved in ccp1-induced cell proliferation. Induction of Sprouty (SPRY) upon FGF2 treatment was accelerated in
ccp1 over-expressing cells.
Conclusions: All together, the results showed that ccp1 regulates cell number by promoting proliferation and
suppressing cell death. FGF2 was shown to enhance the effects of ccp1, however, it is likely that other mitogenic
factors present in the serum can also enhance the effects. Whether these effects are mediated by FGF2 influencing
the ccp1 function or by increasing the ccp1 expression level is still unclear. At least some of the proliferative
regulation by ccp1 is mediated by MAPK, however other signaling pathways are likely to be involved.
Background
A previously uncharacterized gene named Coiled-coil
domain containing 115 (Ccdc115) or coiled coil pro-
tein 1 (ccp1) (GeneID: 69668), has been recently iden-
tified downstream of Fibroblast Growth Factor 2
(FGF2) by microarray analysis and its expression pat-
tern was characterized [1]. The ccp1 transcript was
up-regulated upon FGF2 stimulation in primary corti-
cal neuron culture (CNC) derived from mouse
embryonic telencephalon at embryonic day 14.5
(E14.5) and in neuroblastoma cell line, SK-N-SH. In
situ hybridizations revealed that ccp1 was expressed in
the ventricular zone (VZ), a region of the developing
cerebral cortex known to be composed of progenitor
cells undergoing proliferation [2].
The mechanism by which cell proliferation is con-
trolled in the VZ is still not fully understood. A number
of factors, including FGFs, have been shown to regulate
the proliferation of progenitor cells in embryonic Cen-
tral Nervous System (CNS) in vitro [3-7]. FGFs are a
family of 22 polypeptides known to play various roles in
neural development [8,9]. FGF signals are mainly
mediated by high-affinity receptor-type tyrosine kinases,
FGF receptors (FGFRs). FGF signaling plays variety of
roles in neural development and in pathogenesis of
developmental diseases. FGFs are a class of molecules
that regulate proliferation by controlling the length of
the G1 phase. Addition of FGF2 in primary culture pre-
pared from developing cortex at E14-E16 showed short-
ening of the G1 length and increase in proliferative
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divisions, indicating that FGF2 controls cell proliferation
via its control of G1 length [10]. Regulation of cell pro-
liferation is mediated by a complex system of signaling
pathways. One of the core pathways downstream of FGF
is the mitogen-activated protein kinase (MAPK) pathway
[11], which has a central role in transmitting cell prolif-
eration and survival signals [12]. In this pathway, RAS
promotes activation of the serine/threonine protein
kinases Raf1 and MEK1. In addition to controlling RAF
kinases, MAPK may also directly regulate several other
signaling pathway, such as the phosphatidylinositol 3
(PI3) kinase [13].
In this study, ccp1 function was investigated using a
retroviral over-expression system and RNA interference
(RNAi) in vitro. We analysed the effects of altered ccp1
expression in cell proliferation and apoptosis in mouse
embryonic fibroblast (MEF), a neuroblastoma cell line
SK-N-SH, and in NIH3T3. Since ccp1 expression is
found regulated by FGF2, we also investigated the
effects of FGF2 and compared them to those of the
serum in ccp1-expressing cells. Furthermore, by specifi-
cally inhibiting the MAPK pathway with the pharmaco-
logical inhibitor U0126, we further investigated the
involvement of this pathway in ccp1-induced cell prolif-
eration. Our results showed that ccp1 regulates cell
number by promoting proliferation and suppressing cell
death.
Methods
Cell culture
SK-N-SH and MEF cells were maintained in D-MEM,
10% fetal bovine serum (FBS) and 2 mM glutamine.
NIH3T3 were maintained in D-MEM, 10% DCS and
2 mM glutamine. The natural immortalised MEFs were
originally from Dr Nick Dyson (Massachusetts General
Hospital Cancer Center/Harvard Medical School, Char-
lestown, MA [14]. Cells were maintained at 37°C in 5%
CO2. When required, cells were starved in media with-
out serum for 24 h and treated with FGF2 and heparin
as indicated.
Retroviral-mediated expression of ccp1
Single strand cDNA was synthesized as described in
[1]. The retrovirus expression vector pLPC was
obtained from Dr S. Lowe. Phoenix packaging cells
were transfected with pLPC/eGFP or pLPC-ccp1/
eGFP-N vectors using Lipofectamine 2000 (Invitrogen).
Cells were incubated ON in 20% fetal bovine serum
(FBS) media in order to allow virus production.
Immortalized MEF and SK-N-SH cells were infected
with the Phoenix-supernatant. The infection was
repeated three times at intervals of 12 h each. After
the last infection, cells were selected in the presence of
25 mg/ml of puromycin.
RNA interference (RNAi)
Transfection was performed using Lipofectamine 2000
reagent in Optimem media (Gibco) according to the
manufacturer’s instructions (Invitrogen). 50 nM/well of
pre-designed and annealed siRNAs (Ambion) were
used: siRNAi1, sense 5’-aguugaagccuuugacuuctt-3’, anti
sense 5’-gaagucaaaggcuucaacutc-3’; siRNAi2, sense 5’-
ggcaugaaguugaguuaugtt-3’, anti sense 5’- cauaacucaa-
cuucaugcctc-3’. Scramble siRNA was purchased from
Ambion. After 24 h, cells were harvested and RNA
was extracted and used for semi-quantitative RT-PCR.
The primers used were F-338 and R-1096 [1]. Primers
were designated against a DNA sequence with very
high homology between mouse and human DNA.
BrdU assays
BrdU assay was performed using BrdU labeling and
detection Kit I (Roche). Cells were exposed to BrdU for
1 h and fixed in ethanol for 20 minutes (min) at -20°C.
Anti-BrdU antibody was applied for 30 min at 37°C, and
the fluorescein-conjugated secondary antibody for 30
min. Coverslips were mounted with 4’,6 diamidino-2-
phenylindole (DAPI). Photographs were taken using a
Zeiss Axioskop microscope and Axiovision software.
Western blotting
Cells were lysed in Laemmli sample buffer (Biorad) and
analysed on 12% SDS-PAGE. The proteins transferred
to Hybond ECL nitrocellulose membranes (Amersham)
were blocked with 10% dried milk in TBST (20 mM
Tris, pH 7.6, 13.7 mM NaCl, 0.1% Tween 20) for 2 h.
Incubation with the primary antibody was at 4°C over-
night, and with the secondary, for 1 h at room tempera-
ture. Detection was with ECL (Amersham) exposed to
X-ray film (Fuji). Antibodies were anti-ccp1 (1:500; anti-
rabbit and anti mouse; Beatson Laboratories Antibody
Services), anti-ERK, anti-p-ERK (Cell signaling), anti-
Sprouty (Invitrogen) and anti-GFP (Abcam). Densitome-
try analysis was carried out by Quantity One program
(Biorad).
Tunel
TUNEL assays were performed using the In situ Cell
Death Kit-AP (Roche). Cells were serum starved over-
night and then fixed in 4% paraformaldehyde for 1 h at
-20°C and permeabilised in 0.1% Triton X-100, 0.1%
sodium citrate for 2 min at 4°C. The DNA strand breaks
were fluorescently labeled via the TUNEL reaction for
1 h at 37°C. TUNEL-positive cells were detected by
fluorescence (FITC, 520 nm).
Statistics
Student’s t-test was performed to test the significance of
difference in numerical data as appropriate.
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Ethics
Our research conformed to the Helsinki Declaration and
to local legislation.
Results
Morphological changes of the cell upon ccp1 over-
expression
We first established MEF cells stably expressing ccp1
tagged with eGFP at the N-terminus (ccp1/eGFP-N) by
retrovirus approach. The ccp1/eGFP expression vector
was generated by using the retroviral vector pLPC. Expres-
sion levels of ccp1/eGFP-N fusion protein was detected
under the phase contrast microscope and then analysed by
Western Blotting (Figure 1A). The cells stably expressing
ccp1/eGFP-N showed a band of 55 kDa, corresponding to
the expected size of the ccp1/eGFP-N fusion protein
which was detected either with an anti-GFP and the ccp1-
specific antibody produced in house. We have previously
shown that ccp1 is highly expressed in embryonic and
adult brains and up-regulated in SK-N-SH cells after treat-
ment with FGF2 [1]. Therefore we generated stably
expressing cell line of ccp1/eGFP-N in human SK-N-SH
neuroblastoma cell lines (Figure 1B). A specific band of 55
kDa was also observed in this stable line.
In order to identify cellular localization of the ccp1 pro-
tein, analysis with confocal microscopy was carried out in
MEF and SK-N-SH stably expressing ccp1/eGFP-N protein
using an anti-GFP antibody (Figure 1C, a-b, e-f). While con-
trol cells expressing eGFP showed only diffuse fluorescence
signals throughout the cells, the ccp1/eGFP-N protein was
observed in a localized and punctate pattern. Although
ccp1 was mainly present in the cytoplasm in MEF cells, SK-
N-SH cells showed expression also in the nucleus and peri-
nuclear region as observed in primary CNC [1].
Signaling through FGF/FGFR is known to result in
morphological transformation of fibroblasts in vitro,
which may be associated with tumor progression
[15,16]. Morphological transformation of the cell was
observed upon stable expression of ccp1 in MEF and
SK-N-SH (Figure 1C, c-d, g-h). Cells expressing ccp1/
eGFP-N appeared smaller and had a spindle-like pheno-
type compared to the control cells. Morphological trans-
formation in MEF stably expressing ccp1/eGFP-N
protein was also shown by cytoskeletal staining of the
actin filaments, in which actin cytoskeleton actin cytos-
keleton actin cytoskeletonMembrane ruffling is visua-
lized by staining the actin cytoskeleton actin
remodelling and membrane ruffling was indicated upon
ccp1 over-expression (Figure 1C, i-j).
Stable expression of ccp1 leads to an increase in
cell number
Next, in order to determine the function of ccp1 in cell
proliferation, a growth of cells stably expressing ccp1 was
examined in the presence of serum for up to 5 days
(Figure 2). MEF stably expressing ccp1 showed 123%
increase in cell number in one day in culture (Figure 2A).
After 5 days, MEF expressing ccp1 grew 4-fold more
than control, indicating that stable over-expression of
ccp1 promoted cell proliferation. To determine whether
the observed increase in cell number was due an increase
in cells in the S phase, BrdU assay was performed in MEF
and SK-N-SH cells stably expressing ccp1/eGFP-N cul-
tured in the presence of serum (Figure 2B). Cells were
cultured on coverslips in 10% serum for 24 h, incubated
in 10 μM BrdU for 1 h before fixation, and stained with
anti-BrdU antibody. MEF expressing ccp1 showed an
increase in the number of cells in the S phase by 45%
compared to that in control parental MEF and to MEF
expressing eGFP. Similar results were obtained in SK-N-
SH cells expressing ccp1, which showed an increase in
cell proliferation by two-fold compared to the control
and to the SK-N-SH stably expressing eGFP.
In order to determine whether ccp1 could actually
induce cell proliferation independent of growth factor
stimulations, growth of cells were examined in MEF
expressing ccp1/eGFP-N in the absence of serum (Fig-
ure 2C). Control MEF showed a mild increase in cell
number for up to 4 days. In contrast, MEF stably
expressing ccp1/eGFP-N showed a three-fold increase in
cell number at 3 days in culture and then a decrease
was observed on the 4th day. Similarly, BrdU assay was
performed in MEF cells stably expressing ccp1/eGFP-N
and cultured in the absence of serum (Figure 2D). As
expected control parental MEF showed a marked
decrease in BrdU incorporation when compared to cells
grown in the presence of serum (Figure 2B and 2D).
Interestingly, however, MEF expressing ccp1 showed an
obvious increase in the number of cells in the S phase
compared to that in control parental MEF even in the
absence of serum.
These data indicated that ccp1 over-expression pro-
moted cell proliferation in both the presence and
absence of serum.
FGF2 treatment increases the proliferative effect of ccp1
Ccp1 has been previously identified as a downstream
gene of FGF2 [1]. Therefore, to further investigate
whether ccp1 is an effecter of FGF2 mediating its sig-
nal in cell proliferation, control parental MEF expres-
sing GFP and MEF expressing ccp1/eGFP-N were
starved overnight and treated with 50 ng/ml FGF2 or
with 10% serum (Figure 3A). BrdU was added to the
culture for 24 h. In the control where no ligand or
serum was added, MEF expressing ccp1 showed
increase in BrdU incorporation in comparison to par-
ental MEF. Further increase in BrdU incorporation was
observed in cells treated with FGF2. However in MEF
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Figure 1 Establishment of cell lines stably expressing the ccp1 protein. Cell lines stably expressing ccp1/eGFP fusion proteins were
generated using retroviral approach. (A) The expression of ccp1/eGFP fusion protein was analyzed in MEF cell lines using polyclonal sera raised
against ccp1 (left panel) and GFP antibody (right panel). The ccp1/eGFP fusion protein was detected as a single band at the expected molecular
weight of 55 kDa. (B) The expression of ccp1/eGFP fusion protein was also analyzed in neuroblastoma, SK-N-SH cell lines using GFP antibody.
7.5% SDS-PAGE. (C) MEF (a-d, i-j) and SK-S-NH (e-h) were cultured in the presence of serum. (a-b, e-f) Cells were analyzed using anti-GFP
antibody and confocal microscopy. (a) Mostly nuclear and weak cytoplasmic localization was diffusely observed in the eGFP protein stably
expressed in MEF. (b) The ccp1/eGFP fusion protein stably expressed in MEF was observed in the cytoplasm in punctate spots. (c) Control MEF
presented a typical fibroblast flat shape. (d) MEF expressing ccp1/eGFP fusion protein appeared smaller and shaped spindle-like. (e-h) Similar
pattern was observed in SK-N-SH cells. (i-j) Filamentous actin was visualized with Teas Red-conjugated phalloidin (red) in MEF control and MEF-
ccp1/eGFP. Nuclei were stained using DAPI (blu). Scale bar in a-b, e-f, i-j = 25 μm (line) and in c-d, g-h = 200 μm (dotted line).
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expressing ccp1, the level of increase by FGF2 did not
reach the level achieved by serum. After stimulation
with serum, more cells in S phase were observed in
comparison to the FGF2 treated cells in MEF expres-
sing ccp1. Parental MEF showed incorporation of
BrdU in 28.5% and 26.8% of cells when treated with
FGF2 and serum, respectively. In contrast, MEF
expressing ccp1 showed the BrdU incorporation in
57.4% and 83.1% of cells in FGF2 and serum, respec-
tively. These data suggested that effects of ccp1 in cell
proliferation were enhanced by FGF2, and that other
mitogens present in the serum are likely to also
enhance these effects.
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Figure 2 Stable expression of the ccp1 protein resulted in an increase in cell number. (A) Parental MEF and MEF expressing ccp1/EGFP
fusion protein were cultured in the presence of serum over 5 days. (B) MEF expressing the ccp1/eGFP protein showed increase in BrdU
incorporation in comparison to control cells. BrdU incorporation was also examined in SK-N-SH cells. Cells expressing the ccp1/eGFP protein
showed an increase in BrdU incorporation in comparison to control. (* p < 0.05) (n = 3). (C) In the absence of serum, 3-fold increase in cell
number was observed in MEF stably expressing ccp1/eGFP fusion protein in comparison to parental MEF at 3 days of culture. The number of
cells expressing ccp1/eGFP decreased afterwards. (D) MEF expressing the ccp1/eGFP protein showed increase in BrdU incorporation in
comparison to control cells also when cultured in absence of serum. Scale bar = 200 μm.
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We showed that ccp1 expression in MEF and SK-N-
SH cells caused a change in cell morphology (Figure
1C). Here we addressed whether FGF2 played a role in
ccp1-induced changes in cell morphology, compared to
the effect of serum. Control parental MEF and MEF
expressing ccp1/eGFP-N were starved overnight and
treated with either 50 ng/ml FGF2 in the presence of
10 μg/ml heparin, or serum, for 24 h (Figure 3B). The
morphological changes observed in ccp1-expressing cells
became more prominent upon stimulation with FGF2
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Figure 3 Effects of mitogen stimulation on ccp1-induced cell proliferation and cell shape changes. MEF expressing ccp1 and parental
MEF were cultured in absence of serum overnight and treated with FGF2 and heparin or 10% serum, for 24 h. (A) One hour pulse label of BrdU
was performed and BrdU incorporation was calculated as described before (**p < 0.005). (B) Parental MEF and MEF stably expressing ccp1 were
cultured in absence of serum overnight (a-b) and treated with FGF2 and heparin (c-d) or serum (e-f). Upon FGF2 stimulation for 24 h, MEF stably
expressing ccp1 showed more drastic changes in cell shape. Similar changes were observed in the presence of serum.
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(Figure 3B, c-d) and changes were similar upon treat-
ment with serum (Figure 3B, e-f).
BrdU incorporation is inhibited when ccp1 expression is
knocked down by RNAi
To further confirm the role of ccp1 in cell proliferation,
RNAi was performed. NIH3T3 cells were transfected
with small interfering RNAs (siRNAs) specific for ccp1
(siRNA1 and siRNA2) and a scramble siRNA as a con-
trol. After 24 h, mRNA levels of ccp1 were measured by
semi-quantitative RT-PCR. Ccp1 expression was reduced
in cells transfected with the siRNA1 and siRNA2 com-
paring to scramble siRNA and this was confirmed by
densitometry analysis (Figure 4A right panel). Next,
BrdU assays were performed in cells transfected with
ccp1 siRNAs (Figure 4B). Upon knockdown of ccp1
expression, cells showed a decrease in BrdU incorpora-
tion compared to the scramble siRNA-treated cells.
Therefore, these data further confirmed the role of ccp1
in promoting cell proliferation.
Ccp1 stable expression protects cells from apoptosis
Apoptosis or programmed cell death is an important
physiological process that contributes to final cell num-
ber in the tissue. In order to determine whether apopto-
sis was involved in the increase in cell number upon
over-expression of ccp1 (Figure 2), TUNEL assay was
performed in SK-N-SH cells (Figure 5). After 24 h of
plating, cells were cultured in the absence of serum for
1, 2, and 3 days before TUNEL assay was performed. At
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Figure 4 Cell proliferation was inhibited when ccp1 expression was knocked down in NIH3T3 cells. (A) Ccp1 expression was knocked
down in NIH3T3 cells using specific ccp1-siRNA (siRNA1 and siRNA2). Ccp1 expression after silencing was assessed by RT-PCR. Actin amplification
was performed to show equal sample loading. Densitometry analysis showed the fold changes. (B) BrdU assay performed in absence of serum
showed that cell proliferation in cells knocked down with ccp1 decreased compared to the scramble siRNA-treated cells (n = 3, ** = p < 0.005).
Cells transfected with Scramble siRNA did not show significant reduction in cell proliferation.
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day 1, no apoptotic cells were detectable in SK-N-SH
cells expressing ccp1. However a major effect was evi-
dent at day 2 and 3, where SK-N-SH cells expressing
ccp1 showed a 5 and 7 fold decrease in apoptotic cells
in comparison with SK-N-SH cells expressing eGFP,
respectively. These data suggest that ccp1 plays a role in
suppressing cell death.
Effects of MEK inhibitor, U0126, in cell proliferation upon
ccp1 over-expression
The MAPK signaling is involved in cell proliferation and
is one of the core signaling pathways of FGF [11].
Therefore, to identify the signaling mechanism of cell
proliferation promoted by ccp1, MAPK signaling was
investigated in MEF expressing ccp1/eGFP-N. In order
to inhibit this signaling pathway and see its effects in
cell proliferation, the MEK inhibitor, U0126, was used
in the BrdU assays. First, the optimal concentration of
U0126 was determined in the culture system used (Fig-
ure 6A). Treatment with 10 μM U0126 resulted in a
10.4% reduction in cell proliferation in comparison to
untreated cells. 20 μM U0126 caused a 45.3% decrease
in proliferation in comparison to the untreated
cells. DMSO alone did not show any effect at this con-
centration. Because of DMSO toxicity at 30 μM, we
selected the concentration of 20 μM.
Control MEF expressing eGFP and MEF expressing
ccp1/eGFP-N were cultured overnight in the absence of
serum, in the presence and absence of 20 μM U0126
(Figure 6B). The effectiveness of U0126 was addressed in
these cells by Western blotting and densitometry analy-
sis, which confirmed reduced phosphorylated ERK upon
treatment (Figure 6E). In the absence of U0126, an
increase in BrdU incorporation was detected in the MEF
stably expressing ccp1 compared to the control MEF
(Figure 6B). Upon treatment by U0126, although BrdU
incorporation remained similar in control MEF, a
decrease was observed in MEF expressing ccp1. The
effects of MEK inhibition was also analysed in cells trea-
ted with FGF2 and 10 μg/ml heparin (Figure 6C), as well
as with 10% serum (Figure 6D). BrdU incorporation was
partially inhibited in control MEF and in MEF expressing
ccp1. This indicates that MAPK may play a partial role in
cell proliferation promoted by ccp1 over-expression,
however there are signaling pathways other than MAPK
that are likely to be also involved in this process.
MAPK signaling upon ccp1 over-expression
We have also performed Western blotting to analyze
activation of MAPK signaling using anti p-ERK antibody
and densitometry analysis. Unexpectedly, ccp1-expres-
sing MEF showed a decrease in ERK phosphorylation in
the steady state culture under serum (Figure 7A). To
characterize further the nature of ERK phosphorylation
in ccp1-over-expressing cells, levels of p-ERK were
examined upon either FGF2 or serum stimulation over
time. Cells were starved overnight and treated with 50
ng/ml FGF2 in the presence of 10 μg/ml heparin for a
short time period of up to 15 min (Figure 7B). Control
MEF showed a gradual activation of ERK as early as 5
min of stimulation. In contrast, a similar but more sig-
nificant increase was observed in the cells expressing
ccp1 as early as 5 min. In contrast, no obvious differ-
ence in the level of p-ERK was detected between the
control and the ccp1 expressing cells in the presence of
10% serum (Figure 7C). These data suggests that ccp1
expression may modulate ERK phosphorylation upon
treatment with FGF2.
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Figure 5 Stable expression of the ccp1 protein reduced apoptosis in the absence of serum. TUNEL assay was performed in SK-N-SH cells
stably expressing ccp1/eGFP protein and eGFP alone as a control. Cells were cultured in the absence of serum for three days. The number of
cells that went through apoptosis increased in the control, up to 15.9 ± 2.6% of total number of cells visualized by DAPI on the third day. In
contrast, apoptotic cells in cells expressing ccp1/eGFP protein remained low, up to 2.3 ± 1.8% (n = 3) (**p < 0.005).
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Figure 7 p-ERK and SPRY levels in ccp1 over-expressing cell. (A) p-ERK was decreased in ccp1-expressing MEF in the steady state of culture
under serum. (B) Cells were starved and treated with FGF2 for time indicated. Western Blotting was performed to examine levels of p-ERK. (C) A
similar experiment was carried out for a treatment with serum. (D) MEF expressing ccp1 were cultured in absence of serum for 24 h and treated
with 50 ng/ml FGF2 in the presence of 10 ug/ml heparin for time indicated. Levels of SPRY were analysed by Western Blotting. 7.5% SDS-PAGE
gels were used. Densitometry analysis showed the fold changes for each blot, showing changes in p-ERK1/2 (A-C) and Spry2 (D).
Pellicano et al. BMC Cancer 2010, 10:657
http://www.biomedcentral.com/1471-2407/10/657
Page 10 of 12
MAPK signaling events are regulated by a negative-
feedback loop through Sprouty (SPRY) proteins [17].
SPRY expression is induced by MAPK signaling upon
growth factor stimulation, such as FGF2 [18]. Therefore
we addressed whether ccp1 could induce SPRY feedback
regulatory activity. Levels of SPRY were analysed by
Western blotting in control and ccp1 expressing MEF
using a pan-SPRY antibody followed by densitometry
analysis (Figure 7D). MEF expressing ccp1 were cultured
in the absence of serum overnight and treated with 50
ng/ml FGF2 in the presence of 10 μg/ml heparin for up
to 24 h. In the control MEF, the level of SPRY was low
at time 0 and gradually increased upon FGF2 stimula-
tion over the time. In contrast, in the MEF expressing
ccp1, the level of SPRY was higher than in the control
MEF from the time point 0 and reached the maximum
level observed in the presence of FGF2 at 6 hours.
Discussion
In this study, we have investigated the potential role of
ccp1, with a hypothesis that ccp1 may be a downstream
effecter of FGF2, promoting cell proliferation and pro-
tecting from apoptosis. We show here that ccp1, a gene
expressed in embryonic and adult brain [1], may regu-
late cell morphology, proliferation and programmed
death in normal fibroblast and in neuroblastoma cells.
We have demonstrated that morphological transfor-
mation occurred in MEF and SK-N-SH cells under
stable over-expression of ccp1 (Figure 1). This effect
was observed both in the presence or absence of FGF2
or serum (Figure 3). A long-term culture, for example,
of neurite outgrowth or growth of cells in soft agar, may
further clarify the effect of ccp1 in morphological trans-
formation in the presence or absence of FGF2 in the
future. Growth curve and BrdU incorporation in the
presence of serum showed that ccp1 expression is able
to promote proliferation up to 5 days in culture (Figure
2). Similar results were observed in the absence of
serum, suggesting that ccp1 is able to induce prolifera-
tion without mitogen stimulation (Figure 2 and 3).
Reduction of ccp1 level by RNAi dramatically reduced
SK-N-SH cell proliferation, providing further evidence
that ccp1 can induce cell proliferation (Figure 4). In
addition, we have showed that ccp1 plays a role in sup-
pressing cell death (Figure 5). Whether extrinsic from
intrinsic pathways are involved in the suppression of
apoptosis by ccp1 is unknown and will need further
investigation.
Although both FGF2 and serum treatment enhanced
the increase in cell proliferation upon ccp1 over-expres-
sion, the effect of FGF2 did not reach that of the serum
(Figure 3 and 6). Therefore it is likely that other mito-
genic factors present in the serum can also enhance this
ccp1 activity. In addition, it was shown that in the
absence of serum, ccp1-induced proliferation was par-
tially inhibited by U0126 (Figure 6B). In contrast, in
cells treated with FGF2, the inhibition was less promi-
nent in MEF expressing ccp1 than control MEF (Figure
6C, D). This indicates that MAPK may play only a par-
tial role in cell proliferation promoted by ccp1 over-
expression, and that there are signaling pathways other
than MAPK that are likely to be also involved in this
process. For example, ccp1 activity could be regulated
by several signaling pathways, such as the PI3K/AKT
pathway. The use of inhibitors of the AKT pathway,
such as an mTor inhibitor, rapamycin, may be useful in
the future to clarify this point.
It is still unclear how ccp1-induced proliferation is
enhanced by FGF2 or serum, in particular, either as a
consequence of an increased expression of endogenous
ccp1 induced by mitogens such as FGF2 [1], or func-
tional enhancement of ccp1 activity by these factors.
Ccp1 expression was able to increase ERK phosphor-
ylation immediately after the treatment with FGF2
(Figure 7B). This could be the bases of ccp1-induced
cell proliferation observed in Figure 6. However, ccp1-
expressing MEF showed a decrease in ERK phosphory-
lation in the steady state culture under serum (Figure
7A). As the decrease in MAPK signaling could be due
to the presence of the feedback loop such as Sprouty
(SPRY) proteins [17], we analysed the SPRY levels (Fig-
ure 7D). In MEF expressing ccp1, the level of SPRY
was already higher than in the control MEF at the
time point 0, however at 6 hours, it reached the maxi-
mum level observed in the presence of FGF2. This
may indicate that ccp1 expression accelerated the
induction of SPRY level, possibly due to activation of
MAPK signaling. However it is remains unclear, why
pERK was suppressed upon ccp1 over-expression in
the steady state of culture. On the other hand, main-
tained increase in SPRY levels in ccp1-overexpressing
cells (Figure 7D) may explain the decrease in cell
growth observed in the absence of serum at 4 days of
treatment (Figure 2C).
Aberrant activation of FGFs and their receptors lead
to several pathologies, including cancer [19]. Study of
ccp1 function in promoting proliferation and suppres-
sing cell death would be interesting in aiming a better
understanding of tumor formation. Further experiments
using knockdown system of ccp1 are necessary to
address the requirement of ccp1 in mediating FGF sig-
naling in cell proliferation and apoptosis, possibly using
multiple cell lines. Although unlikely, a potential cannot
be excluded that the siRNA regulates the protein level
of ccp1 differently from that of the mRNA. This has to
be addressed in the future experiments.
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Conclusions
This study has shown that ccp1 regulates cell prolifera-
tion and cell death. Although FGF2 enhanced the effects
of ccp1, other mitogenic factors such as MAPK, are
likely taking part in enhancing the effects of ccp1.
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